Johnson & Johnson (NYSE:JNJ) Stock Price Down 5.2% – What’s Next?

Johnson & Johnson (NYSE:JNJ)’s stock price traded down 5.2% during trading on Tuesday. The stock traded as low as $252.27 and last traded at $250.00. 1,295,679 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 7,911,786 shares. The stock had previously closed at $263.73.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings per share were $2.59 versus the $2.53 consensus, while revenue rose 5.9% year over year to $25.40 billion, slightly above estimates. Growth in Innovative Medicine helped support results. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Full-year outlook was raised: J&J now expects 2026 adjusted EPS of approximately $11.05 to $11.15, signaling confidence in its operating momentum despite ongoing portfolio challenges. Johnson & Johnson reports Q3 2026 results
• Positive Sentiment: Dividend maintained: The board declared a quarterly dividend of $1.34 per share, payable December 8, reinforcing J&J’s appeal to income-focused investors. Johnson & Johnson Announces Quarterly Dividend
• Positive Sentiment: New long-term clinical data for TREMFYA showed sustained efficacy in Crohn’s disease, supporting the company’s pharmaceutical pipeline and efforts to offset Stelara-related pressure. TREMFYA Crohn’s disease data
• Neutral Sentiment: J&J is leaning toward spinning off its hips-and-knees business, a move that could sharpen the company’s focus but also creates execution and separation risks. J&J hips-and-knees spinoff
• Negative Sentiment: Reported profitability declined: Third-quarter EPS fell from $2.80 a year earlier, with special charges causing a sharp drop in reported profit despite higher sales. Johnson & Johnson Q3 profit report
• Negative Sentiment: MedTech remains a key concern: Surgery revenue declined, with Middle East conflict disrupting medical-device sales. The weakness raises questions about whether a potential spinoff can resolve the segment’s operational problems. Can a Spinoff Fix Johnson & Johnson’s MedTech Problem?

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. Citigroup lifted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $287.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, September 22nd. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Finally, Scotiabank restated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Johnson & Johnson Stock Performance

The company has a market cap of $592.71 billion, a PE ratio of 28.50, a PEG ratio of 2.65 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm’s 50 day moving average is $266.01 and its 200-day moving average is $249.31.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period last year, the company posted $2.80 EPS. The business’s revenue was up 5.9% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 11.18 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently bought and sold shares of the company. National Pension Service grew its holdings in shares of Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc boosted its position in Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after buying an additional 3,133 shares during the period. Elefante Mark B grew its holdings in Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after acquiring an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC increased its position in Johnson & Johnson by 76.1% in the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after acquiring an additional 6,539 shares during the period. Finally, Gradient Investments LLC increased its position in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after acquiring an additional 13,737 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.